Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Tubulin polymerization Inhibitor
Tubulin polymerization-IN-4 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 value of 4.6 μM. This compound effectively disrupts tubulin dynamics, leading to cell cycle arrest at the G2/M phase, induction of apoptosis, and inhibition of both clonogenesis and migration in HeLa cells. Tubulin polymerization-IN-4 serves as a valuable tool in research related to cervical cancer, facilitating the exploration of therapeutic strategies targeting tubulin dynamics. -
Tubulin Inhibitor
Disorazol A is a potent tubulin inhibitor that disrupts microtubule formation by hindering tubulin polymerization. This action effectively blocks mitosis, leading to cell cycle arrest at the G2/M phase and subsequent induction of apoptosis. Additionally, Disorazol A has demonstrated inhibitory effects on L929 mouse fibroblasts, with an IC50 value of 3 pM, and promotes the accumulation of p53 protein within the nucleus. This compound holds potential for research in cancer biology and therapeutic applications. -
Tubulin/NRP1 Inhibitor
Tubulin/NRP1-IN-1 is a dual inhibitor targeting tubulin and neuropilin-1 (NRP1), exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound effectively decreases the viability of prostate tumor cell lines and promotes apoptotic processes. Its unique mechanism makes it a valuable tool for studying cancer biology and exploring potential therapeutic strategies. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-14 is a selective inhibitor of tubulin polymerization, exhibiting an IC50 of 3.15 μM. This compound demonstrates significant anti-vascular and anticancer activities by inducing apoptosis in cancer cells. It is particularly valuable in research focused on cancer biology and therapeutic drug development targeting microtubule dynamics. -
Microtubule/Tubulin Inhibitor
SSE1806 is a microtubule/tubulin inhibitor derived from podophyllotoxin, exhibiting notable anticancer and antiproliferative effects. It demonstrates a GI50 range of 1.29-21.15 μM against cancer cell growth, inducing mitotic abnormalities and G2/M phase cell cycle arrest. Additionally, SSE1806 enhances p53 expression and effectively inhibits the growth of colon cancer organoids, while also overcoming multidrug resistance in MDR-1 overexpressing cell lines, making it a valuable tool for cancer research. -
Tubulin Polymerization Inhibitor
KY216 is a potent tubulin polymerization inhibitor that targets the colchicine-binding site of tubulin, with an IC50 value of 2.61 μM. This compound demonstrates significant biological activity in hindering tubulin polymerization, making it a valuable tool for research applications in non-small cell lung cancer (NSCLC) and breast cancer studies. KY216's mechanism of action positions it as a promising candidate for further investigation into therapeutic strategies against these malignancies. -
Tubulin Polymerization Inhibitor
5HPP-33 is a potent inhibitor of tubulin polymerization with an IC50 of 8.1 μM. It demonstrates significant anti-proliferative activity against leukemia and multiple myeloma cells, exhibiting IC50 values ranging from 1 to 10 μM. 5HPP-33 effectively induces cell cycle arrest at the G2/M phase and promotes apoptosis, making it a valuable tool for cancer research and therapeutic studies targeting microtubule dynamics. -
Microtubule Inhibitor
Kribb3 is a microtubule inhibitor that effectively disrupts microtubule dynamics. It demonstrates significant biological activity by inhibiting cancer cell proliferation with a GI50 range of 0.2-2.5 μM, promoting G2/M phase cell cycle arrest, and inducing apoptosis in HCT-116 cells. Additionally, Kribb3 has shown promising antitumor activity in murine models, making it a valuable tool for cancer research. -
Microtubule Polymerization Inhibitor
UA62784 is a microtubule polymerization inhibitor that selectively interacts with tubulin dimers. As a specific inhibitor of centromere protein E (CENP-E) kinesin, UA62784 is valuable for studying its role in cell division. This compound is particularly relevant for research applications focused on pancreatic cancer and its underlying molecular mechanisms. -
Microtubule Protein Polymerization Inhibitor
AB8939 is a potent microtubule protein polymerization inhibitor that exhibits significant anti-tumor activity, with an IC50 of less than 10 nM against tumor cell proliferation. This compound effectively circumvents resistance mechanisms associated with P-glycoprotein and myeloperoxidase. AB8939 also induces G2/M phase cell cycle arrest and triggers apoptosis in affected cells, making it a valuable tool for cancer research and therapeutic development. -
Microtubule/Tubulin Inhibitor
Sabizabulin hydrochloride is a potent microtubule inhibitor that interacts specifically with the colchicine binding site on tubulin. This compound has demonstrated significant antitumor activity, exhibiting an average IC50 of 5.2 nM in melanoma and prostate cancer cell lines. Its pharmacological profile indicates a low risk of adverse effects, making it a promising candidate for research in cancer therapeutics. -
Tubulin Inhibitor
Tubulin inhibitor 35 is a dual inhibitor targeting tubulin polymerization and topoisomerase I, with an IC50 of approximately 5.69 μM and 50 μM, respectively. This compound demonstrates significant anti-tumor activity, effectively inhibiting the migration and invasion of MGC-803 and RKO cell lines, and inducing apoptosis by arresting the cell cycle at the G2/M phase. With potent efficacy against gastrointestinal tumors, Tubulin inhibitor 35 exhibits an IC50 of 0.09 μM in MGC-803 and 0.2 μM in RKO cell lines, making it a valuable reagent for cancer research applications. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-31 is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. This compound interferes with microtubule dynamics, leading to the induction of apoptosis in cancer cells. Its antitumor activity makes it a valuable tool for investigating cancer biology and developing therapeutic strategies targeting microtubule-dependent processes. -
Microtubule Inhibitor
DAT-230 is a microtubule inhibitor that induces cell apoptosis by promoting microtubule de-polymerization and causing G2/M phase cell cycle arrest. This compound effectively inhibits cell growth both in vitro and in vivo, making it valuable for studies on cancer cell proliferation and the mechanisms of action related to microtubule dynamics. Researchers can utilize DAT-230 to explore therapeutic strategies targeting microtubule function in various cellular contexts. -
Tubulin Inhibitor
Tubulin-IN-51 is a potent tubulin inhibitor with an IC50 of 31 nM, demonstrating oral bioavailability. It promotes tubulin polymerization in vitro and uniquely does not compete with Paclitaxel for binding sites, while inhibiting the interaction of Vinblastine with tubulin. This compound effectively downregulates the G1 phase of the cell cycle and induces apoptosis, leading to significant tumor growth inhibition in various nude mouse xenograft models. Tubulin-IN-51 is valuable for research in cancer biology and therapeutic applications targeting microtubule dynamics. -
Tubulin Inhibitor
Tubulin Inhibitor 13 is a potent compound that targets tubulin polymerization, exhibiting an IC50 value of 16.1 μM. It effectively inhibits cancer cell migration and invasion, promotes apoptosis, and displays significant anticancer activity. Its mechanisms make it a valuable tool for research into cancer biology and potential therapeutic applications. -
Tubulin Inhibitor
Tubulin Inhibitor 32 is a potent agent targeting tubulin, demonstrating significant anti-proliferative effects through the inhibition of microtubule polymerization. This compound induces apoptosis and causes cell cycle arrest at the G2/M phase, making it a valuable tool for cancer research. Its anti-tumor activity further supports its potential applications in studying cancer cell dynamics and therapeutic resistance. -
β-microtubulin Inhibitor
Tubulin inhibitor 43 is a potent β-microtubulin inhibitor that exhibits significant antitumor activity. By impeding β-microtubulin function, it effectively disrupts cancer cell proliferation and growth, ultimately leading to the induction of apoptosis. This compound is valuable for research applications focused on cancer biology and therapeutic development. -
Tubulin and Bmi-1 Inhibitor
APD-94 is a dual inhibitor that targets both tubulin and Bmi-1, disrupting normal tubulin polymerization. This compound downregulates Bmi-1 expression, leading to cell cycle arrest at the G2/M phase and subsequent induction of apoptosis in cancer cells. APD-94 effectively inhibits cancer cell proliferation and demonstrates growth repression of HT29 cell xenografts in NOD/SCID mice. Its applications are particularly relevant in the study of colorectal cancer. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-22 is a potent inhibitor of tubulin polymerization, exhibiting an IC50 of 8.1 μM. This compound effectively arrests the cell cycle at the G2/M phase and induces apoptosis in various cell lines. Its utility in research applications includes studying cell cycle regulation and the mechanisms of apoptosis. -
Tubulin Inhibitor
N-Deacetyl-N-formylcolchicine is a potent inhibitor targeting the colchicine-binding site of tubulin. This compound demonstrates significant antiproliferative activity across multiple cancer cell lines, with IC50 values ranging from 32.61 to 100.28 nM. By inhibiting microtubule polymerization, N-Deacetyl-N-formylcolchicine effectively blocks cell division, induces apoptosis in cancer cells, and suppresses cellular migration. Its application is particularly relevant in the research of lung cancer and various solid tumors. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-43 is a potent tubulin polymerization inhibitor that effectively disrupts cellular microtubule networks by binding to the Colchicine site. This compound promotes cell cycle arrest at the G2/M phase and induces apoptosis in leukemia cells, thereby demonstrating significant anti-cancer activity. Additionally, Tubulin polymerization-IN-43 has been shown to inhibit angiogenesis, making it a valuable tool for cancer research and therapeutic development. -
Tubulin Inhibitor
S-72 is a potent tubulin inhibitor that disrupts tubulin polymerization, leading to mitotic phase cell cycle arrest and apoptosis in cancer cells. Additionally, S-72 has been shown to suppress STAT3 signaling, making it a valuable tool for investigating mechanisms of cancer cell proliferation and survival. Its ability to target both microtubule dynamics and critical signaling pathways highlights its potential in cancer research. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-26 is a potent inhibitor of microtubulin polymerization, specifically targeting the colchicine binding site with an IC50 value of 4.64 μM. This compound exhibits cytotoxic effects by inducing apoptosis and impeding cellular migration and metastasis. It serves as a valuable tool for research applications focused on lung cancer and related studies in tumor dynamics. -
Microtubule inhibitor
IMB5046 is a potent microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis. This compound exhibits significant anti-tumor activity, making it a valuable reagent for cancer research and therapeutic studies focused on cell proliferation and apoptosis mechanisms. -
αβ-Tubulin Inhibitor
αβ-Tubulin-IN-1 is a powerful inhibitor targeting αβ-Tubulin. This compound effectively induces cell cycle arrest at the G2/M phase and promotes efficient apoptosis in cancer cells. Additionally, αβ-Tubulin-IN-1 inhibits tumor cell migration and metastasis, demonstrating significant antitumor efficacy in a dose-dependent manner. It serves as a valuable tool for research into cell cycle regulation and cancer therapeutics. -
Inhibitor of Tubulin Polymerization
DPP-21 is a potent inhibitor of tubulin polymerization, with an IC50 value of 2.4 μM. This compound exhibits significant anti-proliferative effects in various cancer cell lines, including IC50 values of 0.38 nM in HCT116, 11.69 nM in B16, 5.37 nM in HeLa, 9.53 nM in MCF7, 8.94 nM in H23, and 9.37 nM in HepG2. DPP-21 effectively arrests the cell cycle at the G2/M phase, leading to increased apoptosis in tumor cells, as demonstrated by a decrease in Bcl-2 levels and an upregulation of the pro-apoptotic protein Bax. -
Tubulin Inhibitor
3-(3-Phenoxybenzyl)amino-β-carboline is a potent inhibitor of tubulin, specifically targeting αβ-tubulin heterodimers. This compound has been shown to induce G2/M phase cell cycle arrest and subsequent apoptosis in cancer cells. Its significant anticancer activity makes it a valuable tool for research applications aimed at understanding tumor biology and developing novel therapeutic strategies. -
IDO/Tubulin Inhibitor
HI5 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO) and tubulin, demonstrating an IC50 of 70 nM in HeLa cells. It effectively reduces kynurenine production, thereby promoting T cell activation and proliferation. Additionally, HI5 interferes with tubulin polymerization and migration, induces G2/M phase cell cycle arrest, and triggers apoptosis through a mitochondrial-dependent pathway, leading to increased reactive oxidative stress. HI5 is suitable for research in anticancer applications. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-24 is a potent inhibitor of tubulin polymerization. This compound effectively inhibits the proliferation of MCF-7 breast cancer cells, inducing apoptosis and causing cell cycle arrest at the G2/M phase. Additionally, Tubulin polymerization-IN-24 enhances the rate of GTP hydrolysis while inhibiting microtubule assembly, making it a valuable tool for research into cancer biology and cellular dynamics. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-86 is a potent inhibitor of tubulin polymerization that targets the colchicine binding sites on microtubulin, effectively disrupting the microtubule cytoskeleton. This compound demonstrates significant anti-proliferative activity against various cancer cell lines and induces mechanisms such as cell cycle arrest and apoptosis. Additionally, it inhibits cell migration and invasion, contributing to reduced long-term survival of cancer cells. Tubulin polymerization-IN-86 also exhibits efficacy in inhibiting tumor growth in murine models, making it a valuable tool for research in melanoma and related studies. -
β-microtubulin Inhibitor
Tubulin inhibitor 42 (Compound 14b) primarily targets β-microtubulin, exhibiting dose-dependent inhibition with an IC50 of 3.5 µM. This compound disrupts microtubule dynamics, leading to cancer cell cycle arrest in the G2/M phase and triggering apoptosis. Additionally, Tubulin inhibitor 42 demonstrates significant inhibitory effects on angiogenesis, both in vitro and in vivo, ultimately suppressing vascularization and tumor progression. -
Tubulin Inhibitor
SKLB0565 is a potent tubulin inhibitor that demonstrates significant anti-proliferative effects in colorectal carcinoma (CRC) cell lines, with IC50 values ranging from 0.012 μM to 0.081 μM. This compound induces G2/M phase cell cycle arrest and triggers mitochondria-mediated intrinsic apoptosis. Additionally, SKLB0565 effectively inhibits cell migration and disrupts tube formation in human umbilical vein endothelial cells (HUVECs), making it a valuable tool for cancer research and the study of tumor angiogenesis. -
Microtubulin Inhibitor
Microtubulin-IN-1 is a selective inhibitor of microtubulin that targets the colchicine-binding site, leading to disruption of microtubule integrity and upregulation of p53. It demonstrates significant antiproliferative activity across various cancer cell lines, with IC50 values of 2.4 nM for NCI-H460, 1.6 nM for BxPC-3, and 2.07 nM for HT-29. Microtubulin-IN-1 effectively induces cell cycle arrest at the G2/M phase and promotes apoptosis in NCI-H460 cells, making it a valuable tool for cancer research. -
Tubulin Inhibitor
Tubulin polymerization-IN-6 is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. This compound effectively impairs cell migration and tube formation, playing a significant role in anti-angiogenesis. In vivo studies demonstrate that Tubulin polymerization-IN-6 substantially inhibits tumor growth in HT29 xenograft models using Balb/c nude mice, making it a valuable reagent for cancer research. -
VEGFR-2/β-tubulin Inhibitor
VEGFR-2-IN-22 is a dual inhibitor targeting VEGFR-2 and β-tubulin polymerization, demonstrating an IC50 of 19.82 nM against VEGFR-2. This compound promotes apoptosis, making it a valuable tool for studying angiogenesis and cancer biology. Its mechanism of action provides insights into vascular endothelial growth factor pathways and their role in tumor progression. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-17 is a potent inhibitor of tubulin polymerization, effectively disrupting microtubule dynamics. This compound induces depolymerization of tubulin, leading to apoptosis in cancer cells and inhibiting their migratory capabilities. Tubulin polymerization-IN-17 is valuable for research focused on cancer biology and therapies targeting microtubule dynamics. -
Tubulin polymerization inhibitor
Tubulin polymerization-IN-84 is a selective inhibitor of tubulin polymerization that targets the colchicine-binding site, exhibiting an IC50 of 10.9 μM. This compound demonstrates significant antiproliferative effects against various cancer cell lines, including Jurkat, B16-F10, HCT116, and MDA-MB-231, with IC50 values of 60 nM, 380 nM, 138 nM, and 1.054 μM, respectively. Tubulin polymerization-IN-84 induces G2/M-phase arrest and promotes apoptosis in B16-F10 cells, while also suppressing tumor growth in a B16-F10 melanoma model. Additionally, it enhances anti-tumor immunity in conjunction with PD-L1 monoclonal antibodies, making it a valuable reagent for research in T-cell acute lymphoblastic leukemia, melanoma, colon cancer, and breast cancer studies. -
Tubulin Inhibitor
Antitumor agent-68 is a potent tubulin inhibitor that demonstrates significant anticancer activity, with IC50 values of 3.6 μM and 3.8 μM against HeLa and MCF-7 cancer cell lines, respectively. This compound exhibits strong reactive oxygen species (ROS) and DPPH radical scavenging activity in a dose-dependent manner, making it relevant for oxidative stress research. Antitumor agent-68 also features an alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, facilitating advancements in chemical biology applications. -
Microtubule Inhibitor
Polatuzumab vedotin is an antibody-drug conjugate that targets CD79b and functions primarily as a microtubule inhibitor. This compound consists of a humanized anti-CD79b IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a potent agent that disrupts microtubule dynamics. Its unique mechanism makes Polatuzumab vedotin a valuable tool for studying large B-cell lymphomas (LBCL) and exploring therapeutic approaches in related malignancies. Researchers can leverage its targeted delivery system for enhanced therapeutic efficacy in the context of cancer research. -
Microtubule Disassembly Inhibitor
10-Acetyl docetaxel is a microtubule disassembly inhibitor known for its antimitotic activity. As an analog of Docetaxel, this compound effectively disrupts microtubule dynamics, making it a valuable reagent in cancer research. Its mechanism of action can be leveraged to study cellular processes related to mitosis and the development of anticancer therapies. -
Microtubule/Tubulin Inhibitor
DM4-SMe is a potent tubulin inhibitor, primarily targeting microtubules to disrupt cytoskeletal functions. As a metabolite of antibody-maytansinoid conjugates, it serves as a cytotoxic component in antibody-drug conjugates. DM4-SMe exhibits significant biological activity, demonstrating an IC50 of 0.026 nM against KB cells. Additionally, this highly toxic metabolite undergoes oxidation and detoxification by human liver microsomes, which may influence its pharmacokinetic profile in biological systems. -
Tubulin Polymerization Inhibitor
Fmoc-MMAF-OMe is a tubulin polymerization inhibitor that features an Fmoc protecting group. The active component, MMAF, serves as a cytotoxic agent in antibody-drug conjugates (ADCs), making it critical for cancer research. Its ability to disrupt microtubule dynamics positions Fmoc-MMAF-OMe as a valuable tool for studying various cancer pathways and evaluating potential therapeutic strategies. -
Microtubule Inhibitor
S-methyl DM1 is a thiomethyl derivative of Maytansine and functions as a microtubule inhibitor. It binds to tubulin with a dissociation constant (Kd) of 0.93 μM, effectively inhibiting microtubule polymerization and potently suppressing microtubule dynamic instability. Due to its mechanism of action, S-methyl DM1 exhibits significant anticancer properties, making it a valuable reagent for research in cancer biology and therapeutics. -
Microtubule/Tubulin Inhibitor
DM3-SMe is a maytansine derivative that acts as a potent tubulin inhibitor. This compound exhibits remarkable cytotoxic activity in vitro, with an IC50 of 0.0011 nM, making it suitable for various research applications, particularly in the development of antibody-drug conjugates (ADCs). DM3-SMe can be conjugated to antibodies via disulfide or stable thioether bonds, enhancing the targeted delivery of cytotoxic agents in cancer therapy research. -
Microtubule/Tubulin Inhibitor
Tubulysin IM-2 is a potent microtubule and tubulin inhibitor that disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis in tumor cells. This compound serves as a valuable component in antibody-drug conjugates (ADCs) by imparting cytotoxic effects and enhancing therapeutic efficacy. It is particularly useful in cancer research where targeting microtubule dynamics is crucial for investigating tumor progression and treatment responses. -
Tubulin Polymerisation Inhibitor
Tubulin Polymerization-IN-38 is a tubulin polymerization inhibitor that disrupts microtubule dynamics, leading to enhanced apoptosis in cancer cells. As an analogue of Tubulysin, it demonstrates powerful anticancer activity and serves a pivotal role in research applications focusing on cancer treatment and drug discovery. This compound can also be utilized as an antibody-drug conjugate (ADC) cytotoxin, facilitating the synthesis of targeted therapies for oncology research. -
Tubulin Polymerization Inhibitor
Tubulysin D is a potent tubulin polymerization inhibitor that disrupts microtubule dynamics. This highly cytotoxic compound, derived from the myxobacteria Archangium geophyra and Angiococcus disciformis, exhibits significant activity against mammalian cells, including those with multidrug resistance, with IC50 values in the low nanomolar range. By preventing microtubule assembly, Tubulysin D induces cell cycle arrest and apoptosis, making it a valuable tool for cancer research and studies on microtubule-targeting therapies. -
Tubulin Inhibitor
Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate that targets tubulin through a potent microtubule destabilizer, MMAE. The compound combines the ADC linker Bi-Mc-Val-Cit-PAB with MMAE to inhibit microtubule polymerization, effectively disrupting cellular mitotic processes. This reagent is primarily used in antibody-drug conjugate (ADC) research for its potential applications in targeted cancer therapies. -
Tubulin Inhibitor
PC5-VC-PAB-MMAE is a potent tubulin inhibitor linked to an antibody-drug conjugate (ADC) via the PC5-VC-PAB linker. This compound demonstrates significant biological activity by disrupting microtubule dynamics, thereby inhibiting cell proliferation. It serves as a valuable tool for research applications focused on cancer therapy and the study of microtubule-targeting agents.
